

Title (en)  
P/GF-1 COMPANION DIAGNOSTIC METHODS AND PRODUCTS

Title (de)  
P/GF-1-BEGLEITDIAGNOSTIKVERFAHREN UND -PRODUKTE

Title (fr)  
PROCÉDÉS DE DIAGNOSTIC PAR COMPAGNON P/GF-1 ET PRODUITS

Publication  
**EP 2300825 A4 20120425 (EN)**

Application  
**EP 09767690 A 20090617**

Priority  

- US 2009047714 W 20090617
- US 8917208 P 20080815
- US 7362408 P 20080618
- US 11006308 P 20081031
- US 48511409 A 20090616

Abstract (en)  
[origin: WO2009155381A1] The present disclosure relates to, among other things, methods for determining whether a subject receiving treatment with a drug has obtained an efficacious blood level of the drug. Moreover, the present disclosure also relates to methods of determining whether a subject predisposed to or suffering from a disease will benefit from treatment with a drug, and the response of a subject receiving treatment (e.g., such as for cancer) by monitoring biomarkers of angiogenesis. In particular, the disclosure relates to P/GF-1 companion diagnostic methods and products.

IPC 8 full level  
**G01N 33/574** (2006.01); **C07K 16/22** (2006.01); **G01N 33/74** (2006.01)

CPC (source: EP)  
**G01N 33/574** (2013.01); **G01N 33/74** (2013.01); **G01N 2800/50** (2013.01); **G01N 2800/52** (2013.01)

Citation (search report)  

- [A] US 2007254295 A1 20071101 - HARVEY JEANNE [US], et al
- [A] US 2007037224 A1 20070215 - HAMER PETER J [US], et al
- [A] CHIUNG-NIEN CHEN ET AL: "The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer", CANCER LETTERS, vol. 213, no. 1, 1 September 2004 (2004-09-01), pages 73 - 82, XP055020729, ISSN: 0304-3835, DOI: 10.1016/j.canlet.2004.05.020
- [Y] EBOS JOHN M L ET AL: "Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 104, no. 43, 23 October 2007 (2007-10-23), pages 17069 - 17074, XP055020654, ISSN: 0027-8424
- [Y] SOO ET AL: "The effect of varying doses of ABT-869 on biomarkers of angiogenesis and their correlation with pharmacodynamic outcome", no. Abst. 14535, May 2008 (2008-05-01), pages 1 - 2, XP002670638, Retrieved from the Internet <URL:http://tinyurl.com/847l6aq> [retrieved on 20120229]
- See references of WO 2009155381A1

Citation (examination)  
ALBERT D H ET AL: "Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, vol. 5, no. 4, 1 April 2006 (2006-04-01), pages 995 - 1006, XP002403181, ISSN: 1535-7163

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

DOCDB simple family (publication)  
**WO 2009155381 A1 20091223**; CA 2728449 A1 20091223; CN 102224419 A 20111019; EP 2300825 A1 20110330; EP 2300825 A4 20120425; JP 2011525241 A 20110915; MX 2010014228 A 20110329

DOCDB simple family (application)  
**US 2009047714 W 20090617**; CA 2728449 A 20090617; CN 200980132199 A 20090617; EP 09767690 A 20090617; JP 2011514788 A 20090617; MX 2010014228 A 20090617